IPSC - NASDAQ
Century Therapeutics, Inc.
$2.17
-0.34%Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live Snapshotipsc
Total Liabilities
Last Annual Value
64.77M
3-Year CAGR
-29%
5-Year CAGR
-21%
10-Year CAGR
-10%
Century Therapeutics, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Century Therapeutics, Inc. NASDAQ:IPSC | 64.77M | -28.3% | 9.5% | N/A | |
 Equillium, Inc. NASDAQ:EQ | 3.29M | -51.0% | -29.5% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 15.78M | -13.6% | -2.5% | 30.5% | |
 BioAtla, Inc. NASDAQ:BCAB | 38.16M | -8.0% | -2.6% | N/A | |
 MAIA Biotechnology, Inc. AMEX:MAIA | 7.33M | 1.1% | 27.8% | N/A | |
 Q32 Bio Inc. NASDAQ:QTTB | 19.76M | -55.9% | -14.0% | 11.4% | |
 CalciMedica, Inc. NASDAQ:CALC | 5.38M | 10.2% | 5.8% | N/A | |
 INmune Bio, Inc. NASDAQ:INMB | 7.46M | -26.6% | -17.7% | 28.7% | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 44.14M | -0.7% | 45.2% | 25.6% | |
 Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 1.43M | 2.3% | 59.5% | N/A | |
 Karyopharm Therapeutics Inc. NASDAQ:KPTI | 401.34M | 2.1% | 0.8% | 36.3% |
Century Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your IPSC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.